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Abstract
Background: Pediatric antiretroviral therapy (ART) has been shown to substantially reduce morbidity and mortality
in HIV-infected infants and children. To accurately project program costs, analysts need accurate estimations of
antiretroviral drug (ARV) costs for children. However, the costing of pediatric antiretroviral therapy is complicated by
weight-based dosing recommendations which change as children grow.
Methods: We developed a step-by-step methodology for estimating the cost of pediatric ARV regimens for
children ages 0–13 years old. The costing approach incorporates weight-based dosing recommendations to provide
estimated ARV doses throughout childhood development. Published unit drug costs are then used to calculate
average monthly drug costs. We compared our derived monthly ARV costs to published estimates to assess the
accuracy of our methodology.
Results: The estimates of monthly ARV costs are provided for six commonly used first-line pediatric ARV regimens,
considering three possible care scenarios. The costs derived in our analysis for children were fairly comparable to or
slightly higher than available published ARV drug or regimen estimates.
Conclusions: The methodology described here can be used to provide an accurate estimation of pediatric ARV
regimen costs for cost-effectiveness analysts to project the optimum packages of care for HIV-infected children, as
well as for program administrators and budget analysts who wish to assess the feasibility of increasing pediatric
ART availability in constrained budget environments.
Keywords: Antiretroviral therapy, Pediatric HIV, Costs
Background
Currently, 3.4 million children are living with HIV
throughout the world [1]. Early antiretroviral therapy
(ART) has been shown to reduce morbidity and mortal-
ity by 75% in infants infected with HIV [2], yet only
approximately 28% of HIV-infected children in need of
treatment are estimated to be receiving ART [3]. Massive
scale-up of pediatric HIV treatment is needed to prevent
mortality and control the pediatric HIV epidemic, at a
time when resources for HIV care are increasingly con-
strained [4].
To inform the scale-up of pediatric HIV care in the
context of budget constraints, policy makers need accur-
ate projections of antiretroviral drug (ARV) costs and a
clear analysis of the cost-effectiveness of alternative ART
strategies [5-8]. There are four key issues in the estimation
of ARTcosts for children. First, specific medications, such
as lopinavir/ritonavir (LPV/r) and abacavir (ABC), may be
preferred in guidelines for clinical reasons [9-12], but their
costs remain higher as well. Second, fixed-dose combina-
tions (FDCs) are widely used in many ART programs and
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individual component drugs, as well as dosing conveni-
ence and improved adherence [13-15]. The production of
pediatric FDCs has improved drastically over the past few
years, resulting in several dual and triple dispersible for-
mulations [7,16]. However, access to these formulations
remains limited in many programs [17,18]. Third, many
medications are not formulated for easy administration to
infants and very young children, who cannot yet swallow
pills. Such children require either dispersible tablets or
syrup formulations, which are often more expensive than
tablets of the same medication, and in the case of syrups
may be less palatable, compromising adherence and effi-
cacy [19]. Finally, national and international recommenda-
tions regarding pediatric ART treatment are in transition.
Although the WHO publishes guidelines on pediatric HIV
treatment, differences in first and second line treatment
regimens exist between Asian and African care settings
[20]. Additionally, discrepancies between preferred regi-
mens exist within individual countries between different
programs or clinics. In general, programs recommend that
children are transitioned away from syrups to solid formu-
lations as soon as they are able to tolerate them. This re-
duces costs, but local clinical practice may differ from the
national recommendation.
Pediatric antiretroviral therapy use is further compli-
cated by the need for increasing drug doses as children
grow. Patients must be consistently monitored for changes
in weight to ensure that they are receiving adequate doses
of each drug to reach therapeutic levels and fully suppress
the virus, while also avoiding toxicities related to excess
dosing [21]. To evaluate the costs and cost-effectiveness of
various ARV regimens analysts need a defined method-
ology for calculating monthly ARV costs that incorporates
this need for dose modification, but a simple method to
estimate weight-based costs is not widely available. In
2005, the Clinton Health Access Initiative (CHAI) devel-
oped a forecasting tool for pediatric ART which has pri-
marily been used to help countries determine the cost of
pediatric treatment targets and as a tool for ARV procure-
ment planning. The tool estimates the quantities of ARVs
needed based on the makeup of the patient population
and then allows program managers to input current drug
pricing to create a full ARV program budget. However,
CHAI’s model has not been published to date. Two pub-
lished studies have also examined pediatric HIV treatment
costs. One reports the average cost of HIV treatment care
across 43 PEPFAR sites, where 7% of the study population
were pediatric patients [22]. Meyer-Rath et al. completed
a similar analysis for two dedicated pediatric care sites in
South Africa, and further calculated the proportion of
total treatment costs pertaining to ART costs [23]. How-
ever, neither study broke down the cost of pediatric ART
by age, weight or regimen.
Here, we propose a step-by-step approach for deter-
mining the monthly costs of ARV medications for chil-
dren ages 0–13 years in resource-limited settings. We
use published ARV price lists as a basis, and account for
changes in dosing as children grow, as well as the possible
lack of availability of pediatric tablets or co-formulations
in some settings and for some groups of patients. This
methodology can be easily updated using a simple online
tool as new ARV prices are released by international agen-
cies [24,25] or are negotiated by individual governments
[26,27] (see Additional file 1). We hope this approach can
be used by investigators seeking to analyze the cost-
effectiveness of ART strategies for children, as well as by
analysts and program administrators in accurately asses-
sing the costs of potential treatment options for pediatric
HIV patients.
Methods
To estimate the monthly cost of specific ART regimens
for children ages 0–13 years in resource-limited settings,
we developed a 7-step approach.
1. Weight-based doses for pediatric ARV were taken
from Annex E of the 2010 World Health
Organization (WHO) Pediatric Guidelines and
Annex 7 of the upcoming WHO 2013 Consolidated
Pediatric and Adult Guidelines (Table 1)[ 7,28]. The
WHO stratifies dosing recommendations by drug
formulation and by current weight (divided into 7
weight bands: 3–5.9 kg, 6–9.9 kg, 10–13.9 kg,
14–19.9 kg, 20–24.9 kg, 25–34.9 kg, and 35+ kg).
We modeled dosing for all drugs that are currently
recommended in the 2013 WHO guidelines. We
also included doses from the 2010 WHO guidelines
for drugs such as stavudine (d4T) that are no longer
recommended, but still likely to be available in many
pediatric treatment programs [7].
2. Assignment of unit costs for each antiretroviral drug
(Table 2). We next identified publicly available unit
costs for each medication. Unit costs are defined as
cost (in 2012 USD) per tablet, per capsule or per
milliliter of liquid formulation. Due to the wide
variety of drug prices available to resource-limited
countries based on individual agreements with
pharmaceutical companies, we used the CHAI May
2012 ceiling price list as the basis for drug cost
estimates [24]. These ceiling prices represent the
highest level that pharmaceutical companies can
charge for these brand-name products in the
countries that are members of the CHAI
Procurement Consortium, and thus that have
access to the reduced costs drug costs negotiated
by CHAI. As individual countries or programs
may be able to negotiate or obtain access to lower
Doherty et al. BMC Health Services Research 2014, 14:201 Page 2 of 12
http://www.biomedcentral.com/1472-6963/14/201prices for certain formulations, the unit costs
shown here should be taken as a maximum estimate
of drug costs in resource-limited settings. For the
formulations not included in the CHAI 2012 price
list, we used the price list from Mèdecins Sans
Frontières (MSF), and chose the price estimate
for the generic version of the drug formulation if
available [25]. Any other price list could be
substituted for this source of data, including prices
negotiated by other international agencies or
Table 1 Weight-based dosing recommendations for currently recommended and commonly used antiretroviral
drugs [7,28]
WHO dosing recommendations by weight band
Medication (strength) 3-5.9 kg 6-9.9 kg 10-13.9 kg 14-19.9 kg 20-24.9 kg 25-34.9 kg 35+ kg
ABC (20 mg/ml) 3 ml bid 4 ml bid 6ml bid - - - -
ABC (60 mg) 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
ABC (300 mg) - - - - - 1 tab bid 1 tab bid
d4T (1 mg/ml) 6 ml bid 9 ml bid - - - - -
d4T (15 mg) - - 1 tab bid - - - -
d4T (20 mg) - - - 1 tab bid 1 tab bid - -
d4T (30 mg) - - - - - 1 tab bid 1 tab bid
3TC (10 mg/ml) 3 ml bid 4 ml bid 6 ml bid - - - -
3TC (150 mg) - - - 0.5 tab bid 1 tab am + 0.5 tab pm 1 tab bid 1 tab bid
EFV (200 mg) NR NR 1 cap qd (≥3yrs only) 1.5 cap qd 1.5 cap qd 2 cap qd -
EFV (600 mg) - - - - - - 1 tab qd
LPV/r (80/20 mg/ml) 1 ml bid 1.5 ml bid 2ml bid 2.5 ml bid 3 ml bid - -
LPV/r (100/25 mg) NR NR 2 tab am + 1 tab pm 2 tab bid 2 tab bid 3 tab bid -
LPV/r (200/50 mg) - - - - - - 2 tab bid
NVP (10 mg/ml) 5 ml bid 8ml bid 10 ml bid - - - -
NVP (50 mg) 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
NVP (200 mg) - - - - - 1 tab bid 1 tab bid
ZDV (10 mg/ml) 6 ml bid 9 ml bid 12 ml bid - - - -
ZDV (60 mg) 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
ZDV (300 mg) - - - - - 1 tab bid 1 tab bid
ZDV/3TC
A (60 mg/30 mg) 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
ZDV/3TC
A (300 mg/150 mg) - - - - - 1 tab bid 1 tab bid
ZDV/3TC/NVP
B
(60 mg/30 mg/50 mg)
1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
ZDV/3TC/NVP
B
(300 mg/150 mg/200 mg)
- - - - - 1 tab bid 1 tab bid
d4T/3TC (6 mg/30 mg)
C 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
d4T/3TC
C (30 mg/150 mg) - - - - - 1 tab bid 1 tab bid
d4T/3TC/NVP
D (6 mg/30 mg/50 mg) 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
d4T/3TC/NVP
D
(30 mg/150 mg/200 mg)
- - - - - 1 tab bid 1 tab bid
ABC/3TC
E (60 mg/30 mg) 1 tab bid 1.5 tab bid 2 tab bid 2.5 tab bid 3 tab bid - -
ABC/3TC
E (600 mg/300 mg) - - - - - 0.5 tab bid 0.5 tab bid
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz, LPV/r lopinavir/ritonavir, NVP nevirapine, ZDV zidovudine, mg milligrams, ml milliliter,
bid twice daily, qd once daily, NR not recommended, tab tablet, cap capsule, kg kilogram.
A. Pediatric tablet is scored and can be split. Can be crushed and contents mixed with a small amount of water or food and taken immediately.
B. Pediatric tablet is dispersible and may be split. Can be dispersed into a small volume of water and mixed into a small amount of food and taken immediately.
C. Pediatric tablet is dispersible and crushable, can be split.
D. Pediatric tablet is dispersible and crushable, can be split. If unable to swallow, disperse 1 tablet in 2 teaspoons of water.
E. Pediatric tablet is scored and can be split. Can be crushed and contents mixed with a small amount of water or food and taken immediately.
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only the costs of drug products themselves, and
excludes the costs of shipping, or any costs related
to the delivery of ART, such as equipment,
personnel, overhead, or wasting.
3. Calculation of monthly costs for each medication by
weight (Table 3). Assuming an average of 30.4 days
in a month, we calculate the monthly cost for each
medication by WHO weight band as follows:
Monthly cost ¼ Average dose per day  
unit cost per drug  
30:4 days per month
Average daily dose (in mg, ml, tablet, or capsule/
day) is found in Table 2 and unit cost (in USD/mg,
ml, tablet, or capsule) is found is Table 3 for each of
the drugs in this analysis.
4. Probability of being in each WHO weight band by
age (Table 4). Although most clinical guidelines
regarding ARV dosing recommendations are based
on a child’s weight, rather than current age [17],
most policy recommendations, such as the WHO
criteria for ART initiation, are based on a child’s age
at presentation to care [7]. Thus, it is useful to
translate the weight-based ARV costs calculated in
Step 3 (Table 3) into age-based ARV costs.
Weight-by-age distributions were obtained from the
WHO Child Growth Standards for children <5 years
of age and from the Centers for Disease Control and
Prevention (CDC) Growth Charts for children ≥5
years [30,31]. Both growth charts contain the
Lambda-Mu-Sigma (LMS) parameters (the power in
the Box-Cox transformation (L), the median (M),
and the generalized coefficient of variation (S))
needed to generate exact percentiles and z-scores by
age and gender [32].
Although few data are available on how the weight
distribution of HIV-infected children compares to
the weight distribution of the general population of
children the same age, one study found that on
average, HIV-infected children are of lower weight
[33]. To account for lower weights among
HIV-infected children than among the general
population, we first shifted the weight distribution in
the growth charts to a −1.5 z-score (Z) and assumed
the coefficient of variation of the weight distribution
(SHIV) was equal to that of the general population.
To examine the impact of these assumptions, we
conducted sensitivity analyses in which we
recalculated drug costs after varying both the shifted
weight distribution z-score (z-scores of −3 to 0) and
the coefficient of variation (double and half SHIV).
These parameters can also be modified by use of the
online tool.
Using these new weight-by age distributions, we
calculated Z-scores for the upper and lower bounds
of the weight bands used in the WHO dosing
recommendations (3 kg, 5.9 kg, 6 kg, 9.9 kg, 10 kg,
13.9 kg, 14 kg, 19.9 kg, 20 kg, 24.9 kg, 25 kg, and
Table 2 Unit costs, derived from CHAI 2012 Price List [24]
Medication (strength) Unit cost (2012 USD)
ABC (20 mg/ml) $0.06/ml
ABC (60 mg) $0.09/tab
ABC (300 mg) $0.26/tab
d4T (1 mg/ml) $0.01/tab
d4T (15 mg) $0.02/tab
d4T (20 mg) $0.02/tab
d4T (30 mg) $0.03/tab
3TC (10 mg/ml) $0.01/ml
3TC (150 mg) $0.04/tab
EFV (200 mg) $0.11/cap
EFV (600 mg) $0.15/tab
LPV/r (80/20 mg/ml) $0.19/ml
LPV/r (100/25 mg) $0.14/tab
LPV/r (200/50 mg) $0.26/tab
NVP (10 mg/ml) $0.01/ml
NVP (50 mg) $0.05/tab
A
NVP (200 mg) $0.05/tab
ZDV (10 mg/ml) $0.01/ml
ZDV (60 mg) $0.05/tab
B
ZDV (300 mg) $0.12/tab
ZDV/3TC (60 mg/30 mg) $0.05/tab
ZDV/3TC (300 mg/150 mg) $0.15/tab
ZDV/3TC/NVP (60 mg/30 mg/50 mg) $0.07/tab
ZDV/3TC/NVP (300 mg/150 mg/200 mg) $0.19/tab
d4T/3TC (6 mg/30 mg) $0.03/tab
d4T/3TC (30 mg/150 mg) $0.06/tab
d4T/3TC/NVP (6 mg/30 mg/50 mg) $0.04/tab
d4T/3TC/NVP (30 mg/150 mg/200 mg) $0.11/tab
ABC/3TC (60 mg/30 mg) $0.09/tab
ABC/3TC (600 mg/300 mg) $0.58-$1.07/tab
C
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz,
LPV/r lopinavir/ritonavir, NVP nevirapine, ZDV zidovudine, mg milligrams,
ml milliliter, tab tablet, cap capsule.
A. Cost for NVP (50 mg) not reported in CHAI Price List. Mèdecins San
Frontières (MSF) reports a cost of $0.05/tab from manufacturer Aurobindo [25].
B. Cost for ZDV (60 mg) not reported in 2012 CHAI Price List. MSF reports a
cost of $0.05/tab from manufacturer Ranbaxy [25].
C. Cost for ABC/3TC (600 mg/300 mg) not reported in 2012 CHAI Price List.
MSF reports a cost of $0.58-$1.07/tab from manufacturers ViiV, Aurobindo,
Cipla and Matrix [25].
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was then used to convert the z-scores into
cumulative probability estimates. Finally, the
probability of being in each weight band (by age and
gender) was calculated as the cumulative probability
of being above the upper bound of the weight band
subtracted from the cumulative probability of being
below the lower bound of the weight band (or the
area under the curve within the upper and lower
bounds). Assuming an equal proportion of males
and females, these final probabilities by gender were
averaged to estimate the probability of being in
each weight band by age (Table 4).
5. Calculation of monthly costs for each medication by
age (Table 5). We then used the newly defined
probabilities of being in each weight band by age
(Table 4) to calculate monthly medication costs by
age. Monthly medication costs by age were
calculated as the monthly medication cost by weight
band (Table 3) multiplied by the probability of being
in each weight band (Table 4). Several ARVs (such
as ABC) have more than one formulation option
recommended at each age. For these medications,
we provide estimated monthly costs for two
formulation options: 1) children initiate pediatric
liquid formulations and then switch to pediatric
Table 3 Monthly costs for key antiretroviral drugs by weight
Weight bands
Medication (strength) 3-5.9 kg 6-9.9 kg 10-13.9 kg 14-19.9 kg 20-24.9 kg 25-34.9 kg 35+ kg
ABC (20 mg/ml) $10.94 $14.59 $21.89 - - - -
ABC (60 mg) $5.47 $8.21 $10.94 $13.68 $16.42 - -
ABC (300 mg) - - - - - $15.81 $15.81
d4T (1 mg/ml) $3.65 $5.47 - - - - -
d4T (15 mg) - - $1.22 - - - -
d4T (20 mg) - - - $1.22 $1.22 - -
d4T (30 mg) - - - - - $1.82 $1.82
3TC (10 mg/ml) $1.82 $2.43 $3.65 - - - -
3TC (150 mg) - - - $1.22 $1.82 $2.43 $2.43
EFV (200 mg) NR NR $3.34 $5.02 $5.02 $6.69 -
EFV (600 mg) - - - - - - $4.56
LPV/r (80/20 mg/ml) $11.55 $17.33 $23.10 $28.88 $34.66 - -
LPV/r (100/25 mg) NR NR $12.77 $17.02 $17.02 $25.54 -
LPV/r (200/50 mg) - - - - - - $31.62
NVP (10 mg/ml) $3.04 $4.86 $6.08 - - - -
NVP (50 mg) $2.74 $4.10 $5.47 $6.84 $8.21 - -
NVP (200 mg) - - - - - $3.04 $3.04
ZDV (10 mg/ml) $3.65 $5.47 $7.30 - - - -
ZDV (60 mg) $3.04 $4.56 $6.08 $7.60 $9.12 - -
ZDV (300 mg) - - - - - $7.30 $7.30
ZDV/3TC (60 mg/30 mg) $3.04 $4.56 $6.08 $7.60 $9.12 - -
ZDV/3TC (300 mg/150 mg) - - - - - $9.12 $9.12
ZDV/3TC/NVP (60 mg/30 mg/50 mg) $4.26 $6.38 $8.51 $10.64 $12.77 - -
ZDV/3TC/NVP (300 mg/150 mg/200 mg) - - - - - $11.55 $11.55
d4T/3TC (6 mg/30 mg) $1.82 $2.74 $3.65 $4.56 $5.47 - -
d4T/3TC (30 mg/150 mg) - - - - - $3.65 $3.65
d4T/3TC/NVP (6 mg/30 mg/50 mg) $2.43 $3.65 $4.86 $6.08 $7.30 - -
d4T/3TC/NVP (30 mg/150 mg/200 mg) - - - - - $6.69 $6.69
ABC/3TC (60 mg/30 mg) $5.47 $8.21 $10.94 $13.68 $16.42 - -
ABC/3TC (600 mg/300 mg) - - - - - $17.72-$32.53 $17.72-$32.53
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz, LPV/r lopinavir/ritonavir, NVP nevirapine, ZDV zidovudine, mg milligrams, ml milliliter,
NR not recommended, kg kilogram.
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longer recommended or 2) children begin pediatric
tablet formulations as soon as recommended, and
then switch to adult tablet formulations once
pediatric tablets are no longer recommended.
6. Calculation of monthly costs for complete medication
regimens (Table 6). To determine the monthly costs
of complete ART regimens, we combined the
monthly costs by age for each of the component
medications. The WHO 2013 HIV treatment
guidelines currently recommend a first-line, PI-based
regimen (LPV/r +3TC +ABC or ZDV) for all
HIV-infected children less than three years of
age. However, previous WHO guidelines had
recommended an NNRTI-based regimen for
children who had not been exposed to NNRTIs to
prevent mother-to-child transmissions, and in many
countries, NNRTI-based regimens remain the most
readily available first-line option for children. Here,
we present examples of monthly regimen cost
calculations for six commonly used ART regimens:
lopinavir/ritonavir (LPV/r) with zidovudine (ZDV)
and lamivudine (3TC), LPV/r with abacavir (ABC)
and 3TC, LPV/r with stauvudine (d4T) and 3TC,
nevirapine (NVP) or efavirenz (EFV) with ABC and
3TC, NVP or EFV with ZDV and 3TC, and NVP or
EFV with d4T and 3TC. Although d4T is no longer
recommended as a first-line medication, it remains
an option to use in case of anemia where access
to ABC is limited; d4T is commonly used
throughout Africa, largely because of its availability
in inexpensive FDC formulations [7,35].
For each regimen, we derived costs for three key
scenarios that reflect setting-specific variations in
the availability of co-formulated FDCs and the age
at which children are assumed to transition from
liquid to tablet formulations:
Scenario 1 (No FDCs, Late Switch): Coformulations
are not available. Liquid formulations of all drug
components are used until 4 years of age, and then
children switch to pediatric/adult tablets as
recommended by weight-based dosing.
Scenario 2 (No FDCs, Early Switch):
Coformulations are not available. Liquid
Table 4 Probability of being in each WHO weight band by age
Weight bands
Age (years) 3-5.9 kg 6-9.9 kg 10-13.9 kg 14-19.9 kg 20-24.9 kg 25-34.9 kg 35+ kg
0.5 0.246 0.754 0.000 0.000 0.000 0.000 0.000
1 0.001 0.908 0.091 0.000 0.000 0.000 0.000
2 0.000 0.285 0.706 0.009 0.000 0.000 0.000
3 0.000 0.044 0.842 0.113 0.000 0.000 0.000
4 0.000 0.003 0.593 0.398 0.005 0.000 0.000
5 0.000 0.000 0.262 0.696 0.039 0.003 0.000
6 0.000 0.000 0.070 0.779 0.135 0.016 0.001
7 0.000 0.000 0.011 0.638 0.292 0.057 0.003
8 0.000 0.000 0.001 0.403 0.439 0.147 0.010
9 0.000 0.000 0.000 0.197 0.481 0.293 0.029
10 0.000 0.000 0.000 0.073 0.390 0.464 0.073
11 0.000 0.000 0.000 0.019 0.234 0.586 0.162
12 0.000 0.000 0.000 0.003 0.096 0.591 0.310
13 0.000 0.000 0.000 0.000 0.023 0.465 0.512
Abbreviation: kg kilogram.
Weight-by-age standards were tabulated from the WHO Child Growth Standards for children <5 years and from the CDC Growth Charts for children ages ≥5 years
[30,31]. The equations used to generate these age-specific weight distributions rely on the Lambda-Mu-Sigma parameters: the median (M) weight, the generalized
coefficient of variation (S), and the power in the Box-Cox transformation (L) [32,34]. To account for lower weights among HIV-infected children relative to the gen-
eral population of same age, the age-specific weight distributions for HIV-infected children were shifted to the −1.5 z-score of the general population distributions
[33]. The HIV-infected median weight-for-age values (MHIV) were calculated at half-year intervals, where MHIV was equal to the value M*(1 +LSZ)
(1/L). The coefficient
of variation (SHIV) was assumed to be equal to that of children of the same age in the general population. Z-scores for the upper and lower bounds of the
WHO-specified weight intervals for ARV dosing (3 kg, 5.9 kg, 6 kg, 9.9 kg, 10 kg, 13.9 kg, 14 kg, 19.9 kg, 20 kg, 24.9 kg, 25 kg, and 34.9 kg) were calculated by
gender for children ages 0–13 years old, as follows: the z-score of the bound of interest, X, equals ((X/MHIV)
L -1)/L*SHIV. The Norm.S.Dist(z,1) Excel function was used
to convert z-scores into cumulative probability estimates. The probability of being in each weight band (by age and gender) was calculated as the cumulative
probability of being below the upper bound of the weight band subtracted by the cumulative probability of being below the lower bound of the weight band (or
the area under the curve within the upper and lower bounds). Results shown above assume an equal proportion of males and females.
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months of age, and then children switch to
pediatric/adult tablets as recommended by
weight-based dosing.
Scenario 3 (Available FDCs, Early Switch):
Coformulations are available. Coformulated pediatric
tablets, if they exist, are used from birth. If all drug
components are not included in the coformulation,
liquid formulations of the remaining drugs are used
until 6 months of age, and then children switch to
pediatric/adult tablets as recommended by
weight-based dosing.
For example, South Africa currently has access to
most pediatric liquid and tablet formulations, but
co-formulations are not widely available [17,18].
Therefore, when compiling monthly regimen costs
for South Africa, individual liquid or tablet doses
must be used instead of the fixed dose combination
pills (Scenarios 1 and 2). The above scenarios reflect
only three possible assumptions regarding the
settings for pediatric ART availability. Alternate
scenarios can be analyzed with use of the online
tool.
7. Comparison of derived to published costs. After
completion of the six steps above, we compared our
calculated monthly ART costs (by weight) to other
published costs. The WHO has compiled a Global
Price Reporting Mechanism (GPRM) database,
which contains average yearly costs for both adult
and pediatric ARVs, based on international
transactions of HIV, tuberculosis and malaria
medications purchased in resource-limited settings
[36]. Costs for pediatric drug formulations in the
GPRM database are shown only for children
weighing 10kg. Here, we compare both pediatric
and adult GPRM costs to the costs derived for
the most relevant weight band in our analysis
(pediatric: weight bands 6–9.9 kg and 10–13.9 kg
adult: 35+ kg).
Results
1. Weight-based doses for each antiretroviral drug
(Table 1). Table 1 lists the recommended daily dose
of each drug across all seven weight bands used in
the WHO 2010 and 2013guidelines.
2. Assignment of unit costs for each antiretroviral
drug (Table 2). Unit costs for each drug, using
CHAI and MSF costs as an example, are shown in
Table 2 [24,25].
3. Calculation of monthly costs for each medication
and weight band (Table 3). With daily dosing
Table 5 Monthly costs for antiretroviral drugs by age
Age (years)
Drug product 0.5 123456789 1 0 1 1 1 2 1 3
(Formulation)
ABC
A $13.70 $15.26 $19.74 $20.63 $18.57 $15.94 $14.65 $14.70 $15.23 $15.68 $15.89 $15.91 $15.86 $15.82
ABC
B $7.54 $8.46 $10.19 $11.13 $12.06 $13.08 $13.89 $14.57 $15.21 $15.68 $15.89 $15.91 $15.86 $15.82
d4T $5.02 $5.08 $2.43 $1.40 $1.23 $1.22 $1.23 $1.25 $1.31 $1.41 $1.54 $1.67 $1.76 $1.81
3TC $2.28 $2.54 $3.28 $3.32 $2.67 $1.88 $1.49 $1.49 $1.68 $1.90 $2.11 $2.27 $2.37 $2.42
EFV NR NR NR $3.39 $4.01 $4.58 $4.93 $5.09 $5.26 $5.49 $5.76 $5.92 $5.86 $5.56
LPV/r
A $15.91 $17.85 $21.51 $23.51 $25.45 $27.58 $29.21 $30.32 $30.94 $30.75 $29.78 $28.71 $28.31 $28.86
LPV/r
B $15.91 $16.91 $14.11 $13.45 $14.50 $15.93 $16.87 $17.50 $18.41 $19.94 $22.04 $24.37 $26.58 $28.46
NVP
A $4.42 $4.97 $5.74 $6.11 $6.39 $6.68 $6.91 $7.00 $6.84 $6.27 $5.33 $4.32 $3.55 $3.16
NVP
B $3.77 $4.23 $5.09 $5.57 $6.03 $6.52 $6.87 $7.00 $6.84 $6.27 $5.33 $4.32 $3.55 $3.16
ZDV
A $5.02 $5.64 $6.78 $7.25 $7.42 $7.58 $7.78 $8.02 $8.22 $8.23 $8.03 $7.73 $7.47 $7.34
ZDV
B $4.19 $4.70 $5.66 $6.19 $6.70 $7.26 $7.69 $8.01 $8.22 $8.23 $8.03 $7.73 $7.47 $7.34
ZDV/3TC $4.19 $4.70 $5.66 $6.19 $6.70 $7.27 $7.72 $8.12 $8.50 $8.82 $9.01 $9.09 $9.12 $9.12
ZDV/3TC/NVP $5.86 $6.58 $7.93 $8.66 $9.38 $10.17 $10.79 $11.29 $11.71 $11.96 $11.96 $11.82 $11.67 $11.58
d4T/3TC $2.51 $2.82 $3.40 $3.71 $4.02 $4.35 $4.61 $4.76 $4.82 $4.70 $4.43 $4.09 $3.83 $3.69
d4T/3TC/NVP $3.35 $3.76 $4.53 $4.95 $5.36 $5.81 $6.17 $6.46 $6.71 $6.86 $6.88 $6.82 $6.74 $6.70
ABC/3TC $7.54 $8.46 $10.19 $11.13 $12.06 $13.08 $13.92 $14.69 $15.51 $16.30 $16.92 $17.34 $17.59 $17.69
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz, LPV/r lopinavir/ritonavir. NVP nevirapine, ZDV zidovudine, NR not recommended.
A. Patients are assumed to start the liquid formulation of the medication and then switch directly to pediatric or adult tablets when recommended (by weight).
B. Patients are assumed to start pediatric tablet formulations of the medication at 0.5 years old (or at earliest recommended age) and then switch to adult tablets
when recommended (by weight).
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calculated monthly costs for each drug, stratified by
weight band. Monthly costs for each drug
formulation are shown in Table 3 for each WHO
weight band where that drug formulation is
recommended.
4. Probability of being in each WHO weight band by
age (Table 4).The probability of being in each WHO
weight band by current age and gender was
calculated as described in the Methods. Results are
shown in Table 4 assuming an equal distribution of
males and females.
Sensitivity analyses on weight distributions
demonstrated that monthly drug cost estimates were
fairly robust to changes in assumptions regarding
the weight distribution for HIV-infected children
(z-scores). Assuming no change in weight distribution
between HIV-infected children and the general
population (z-score=0), monthly drug costs by age
changed on average by 9.7%. Monthly drug costs
changed substantially from our original estimates
(>10%) only when we assumed much lower weights
among HIV-infected children (z-score≤− 3). With
improvements in early infant diagnosis and access to
antiretroviral therapy (ART), we anticipate that the
growth distribution for HIV-infected children will
shift toward the WHO growth curves for the general
population, and thus drug costs will remain similar to
Table 6 Monthly regimen costs: Six commonly used regimens
Age (years)
Regimen
A 0 . 5 123456789 1 0 1 1 1 2 1 3
LPV/R+ZDV+3TC
Scenario 1 $23.22 $26.03 $31.57 $34.08 $23.86 $25.07 $26.05 $27.00 $28.30 $30.07 $32.17 $34.36 $36.42 $38.21
Scenario 2 $22.38 $24.15 $23.05 $22.96 $23.86 $25.07 $26.05 $27.00 $28.30 $30.07 $32.17 $34.36 $36.42 $38.21
Scenario 3 $20.10 $21.61 $19.77 $19.64 $21.20 $23.20 $24.59 $25.61 $26.91 $28.76 $31.04 $33.46 $35.69 $37.58
LPV/R+ABC+3TC
Scenario 1 $31.89 $35.65 $44.53 $47.46 $29.22 $30.89 $32.25 $33.56 $35.29 $37.52 $40.03 $42.55 $44.81 $46.70
Scenario 2 $25.73 $27.91 $27.57 $27.91 $29.22 $30.89 $32.25 $33.56 $35.29 $37.52 $40.03 $42.55 $44.81 $46.70
Scenario 3 $23.45 $25.36 $24.30 $24.59 $26.56 $29.01 $30.79 $32.18 $33.92 $36.23 $38.95 $41.71 $44.16 $46.15
LPV/R+D4T +3TC
Scenario 1 $23.22 $25.48 $27.22 $28.23 $18.40 $19.03 $19.58 $20.24 $21.40 $23.25 $25.68 $28.31 $30.71 $32.68
Scenario 2 $23.21 $24.53 $19.81 $18.17 $18.40 $19.03 $19.58 $20.24 $21.40 $23.25 $25.68 $28.31 $30.71 $32.68
Scenario 3 $18.42 $19.73 $17.50 $17.16 $18.52 $20.29 $21.47 $22.26 $23.22 $24.64 $26.46 $28.46 $30.40 $32.15
NVP OR EFV+ ZDV+ 3TC
B
Scenario 1 $11.72 $13.15 $15.80 $13.96 $13.37 $13.72 $14.11 $14.59 $15.15 $15.63 $15.89 $15.92 $15.71 $15.32
Scenario 2 $10.24 $11.47 $14.04 $12.89 $13.37 $13.72 $14.11 $14.59 $15.15 $15.63 $15.89 $15.92 $15.71 $15.32
Scenario 3 $5.86 $6.58 $7.93 $9.57 $10.71 $11.85 $12.65 $13.21 $13.76 $14.31 $14.77 $15.01 $14.98 $14.68
NVP OR EFV+ ABC+3TC
B
Scenario 1 $20.40 $22.77 $28.76 $27.34 $18.73 $19.54 $20.31 $21.16 $22.14 $23.07 $23.75 $24.10 $24.09 $23.80
Scenario 2 $13.59 $15.23 $18.56 $17.84 $18.73 $19.54 $20.31 $21.16 $22.14 $23.07 $23.75 $24.10 $24.09 $23.80
Scenario 3 $11.31 $12.68 $15.28 $14.52 $16.06 $17.66 $18.85 $19.78 $20.76 $21.79 $22.68 $23.26 $23.45 $23.25
NVP OR EFV+ D4T +3TC
B
Scenario 1 $11.72 $12.60 $11.45 $8.11 $7.90 $7.68 $7.64 $7.84 $8.24 $8.81 $9.41 $9.86 $10.00 $9.79
Scenario 2 $11.07 $11.85 $10.80 $8.11 $7.90 $7.68 $7.64 $7.84 $8.24 $8.81 $9.41 $9.86 $10.00 $9.79
Scenario 3 $3.35 $3.76 $4.53 $7.10 $8.03 $8.94 $9.53 $9.85 $10.07 $10.20 $10.18 $10.01 $9.69 $9.25
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz, LPV/r lopinavir/ritonavir, NVP nevirapine, ZDV zidovudine,
A. ARV availability scenarios (see also Methods):
Scenario 1 (No FDCs, Late Switch): Coformulations are not available. Liquid formulations of all drug components are used until 4 years of age, and then children
switch to pediatric/adult tablets as recommended by weight-based dosing.
Scenario 2 (No FDCs, Early Switch): Coformulations are not available. Liquid formulations of all drug components are used until 6 months of age, and then
children switch to pediatric/adult tablets as recommended by weight-based dosing.
Scenario 3 (Available FDCs, Early Switch): Coformulations are available. Coformulated pediatric tablets, if they exist, are used from birth. If all drug components
are not included in the coformulation, liquid formulations of the remaining drugs are used until 6 months of age, and then children switch to pediatric/adult
tablets as recommended by weight-based dosing.
B. Patients on the non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are assumed to receive NVP until age 3, then EFV at age 3 and after
because EFV is not yet approved for children less than 3 years of age or 10kg of weight.
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analyses on the coefficient of variation of the weight
distribution among HIV-infected children (SHIV)a l s o
demonstrated minimal change in monthly drug costs
estimates. First, assuming that SHIV was equal to half
the coefficient of variation of the general population,
we found that monthly drug costs changed by 4.2%,
on average. Second, assuming SHIV was double the
coefficient of variation of the general population, we
found that monthly drug costs changed on average by
6.4%.
5. Calculation of monthly costs for each medication by
age (Table 5). Using the probabilities of being in
each weight band (Table 4) and the monthly costs
for each medication by weight band (Table 3), we
calculated the monthly cost for each medication by
age (Table 5).
6. Calculation of monthly costs for complete medication
regimens (Table 6). Monthly costs for complete
regimens are shown in Table 6, for a variety of
regimens and formulations to reflect the range of
settings described in the Methods. As seen in the
Table, monthly regimen costs do not increase
monotonically as a child grows. This is due to the
switch from more expensive liquid and pediatric
tablet formulations to adult tablet doses. In addition,
the switch from NVP to EFV at age three also
increases overall monthly regimen costs.
7. Comparison of derived to published costs. Compared
to the pediatric drug costs reported in the WHO
GPRM database (based on children weighing 10 kg),
the costs derived in our analysis for children in
weight bands 6–9.9 kg and 10–13.9 kg were fairly
comparable or slightly higher for most formulations
(Table 7). One exception of note is our estimate of
LPV/r syrup costs (80/20 mg/ml). Using our
methodology, the cost range for this formulation in
weight bands 6–9.9 kg and 10–13.9 kg was almost
double that reported in the GPRM ($17.33-$23.10
versus $11.81). All costs estimates from our analysis
for the 35+ kg weight band were also comparable or
slightly higher than the adult formulation costs
reported in the WHO GPRM (Table 8).
Discussion
In this paper, we have provided a standardized method-
ology for estimating monthly pediatric ARV costs that
could allow for greater comparability between future
Table 7 Comparison of pediatric formulation derived
costs to the WHO Global Price Reporting Mechanism
(GPRM) database
Medication (strength) Monthly
costs for
6–9.9 kg
Monthly
costs for
10–13.9 kg
Monthly
costs
A
From
GPRM (Table 3) (Table 3)
ABC (20 mg/ml) $14.59 $21.89 $15.84
ABC (60 mg) $8.21 $10.94 $12.36
d4T (1 mg/ml) $5.47 NR $4.56
d4T (15 mg) NR $1.22 $1.44
3TC (10 mg/ml) $2.43 $3.65 $2.06
LPV/r (80/20 mg/ml) $17.33 $23.10 $11.81
LPV/r (100/25 mg) NR $12.77 $11.20
NVP (10 mg/ml) $4.86 $6.08 $4.81
NVP (50 mg) $4.10 $5.47 N/A
ZDV (10 mg/ml) $5.47 $7.30 $4.82
ZDV (60 mg) $4.56 $6.08 N/A
ZDV/3TC (60 mg/30 mg) $4.56 $6.08 $5.60
ZDV/3TC/NVP (60 mg/30 mg/50 mg) $6.38 $8.51 $8.28
d4T/3TC (6 mg/30 mg) $2.74 $3.65 $3.79
d4T/3TC/NVP (6 mg/30 mg/50 mg) $3.65 $4.86 $4.66
ABC/3TC (60 mg/30 mg) $8.21 $10.94 $13.96
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz,
LPV/r lopinavir/ritonavir, NVP nevirapine, ZDV zidovudine, mg milligrams, ml
milliliter, NR not recommended, N/A not applicable (no cost estimate was
available from the GPRM for this formulation).
A. Pediatric formulations in the WHO GPRM are based on costs for a 10 kg
child. We have shown our calculations from Table 3 for weight bands 6–9.9 kg
and 10–13.0 kg as a comparison.
Table 8 Comparison of adult formulation derived costs to
the WHO Global Price Reporting Mechanism (GPRM)
database
Medication (strength) Monthly costs for
35+kg (from Table 3)
Monthly costs
from GPRM
ABC (300 mg) $15.81 $13.39
d4T (30 mg) $1.82 $1.52
3TC (150 mg) $2.43 $2.36
EFV (600 mg) $4.56 $3.86
LPV/r (200/50 mg) $31.62 $29.47
NVP (200 mg) $3.04 $2.47
ZDV (300 mg) $7.30 $6.98
ZDV/3TC (300 mg/150 mg) $9.12 $7.86
ZDV/3TC/NVP (300 mg/150
mg/200 mg)
$11.55 $9.89
d4T/3TC (30 mg/150 mg) $3.65 $2.99
d4T/3TC/NVP (30 mg/150
mg/200 mg)
$6.69 $4.76
ABC/3TC (600 mg/300 mg) $17.72-$32.53 $22.56
Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz,
LPV/r lopinavir/ritonavir, NVP nevirapine, ZDV zidovudine, mg milligrams, ml
milliliter, NR not recommended, N/A not applicable (no cost estimate was
available from the GPRM for this formulation).
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changing dosing requirements as children grow, and ac-
counts for a range of scenarios for the availability of
pediatric ARV formulations in different countries and set-
tings. To date, there have been no other published proce-
dures for estimating pediatric ART costs by age and by
drug regimen. Meyer-Rath et al. focused their analysis
on calculating the average cost of HIV treatment care
across at two pediatric care sites in South Africa [23].
They further estimated that approximately $25/month
(or 40% of the total per-patient cost over the two years
following treatment initiation) pertained to pediatric
ART costs. Recommended pediatric regimens at these
sites included d4T/3TC/LPV/r for children less than 3
years of age, and d4T/3TC/EFV for children greater
than 3 years of age, with a median age of 4–6 years at
initiation across the two sites. In our analysis, we found
similar monthly costs for d4T/3TC/LPV/r, which
ranged from $18.40-$21.47 for children ages 4–6y e a r s
old, depending on formulation assumptions. However,
our monthly cost estimates for d4T/3TC/EFV ($7.64-
$9.53) for children ages 4–6 years old, were significantly
lower (Table 6). This discrepancy could be due to add-
itional programmatic costs (cold chain storage, shipping
costs, etc.) that may have also been included in the
pediatric ARTcosts in the Meyer-Rath estimation.
In addition, the WHO has compiled average monthly
costs for several pediatric and adult drug formulations in
their GPRM database based on records of international
transactions of HIV, tuberculosis and malaria products
purchased in low- and middle-income countries [36],
focused on 10-kg children. Here, our monthly drug costs
for children in weight bands 6–9.9kg and 10–13.9 kg
were fairly comparable or slightly higher for most for-
mulations (Table 7). We did find, though, that our esti-
mate of the liquid LPV/r formulation (80/20 mg/ml),
which ranged from $17.33-$23.10 was almost double the
cost reported in the WHO GPRM Database ($11.81).
This discrepancy is likely due to the inherent differences
in a ceiling price list (used in our analysis for unit cost
derivation) and the actual transaction costs found in the
GPRM. For example, despite the high cost of liquid
LPV/r (80/20mg/ml), many countries and programs may
have been able to negotiate its purchase at a lower cost
than listed in the CHAI price list because of its key role
in pediatric HIV treatment. In addition, the GPRM
database shows that prices for LPV/r have fallen sub-
stantially over the past five years, from $16.11 to $11.81
per month, demonstrating the rapidly changing eco-
nomic market for this drug. Our costing methodology
described in this paper provides a more detailed and
transparent estimation of ART costs over several ages,
which will be useful in formulating pediatric ART rec-
ommendations in the future.
Our costing procedure has several limitations. First, we
describe a step-by-step approach for calculating drug-
related pediatric ART costs. These costs do not take into
consideration equipment, personnel, overhead, shipping
or opportunity costs that may also be involved in the de-
livery of ART to pediatric patients. We have also excluded
the costs of establishing and maintaining a cold chain
store needed for drugs that require refrigeration. The
costs of these components are infrequently reported, but
will likely inflate LPV/r liquid formulation costs by 5-50%
depending on program level cold chain storage capabil-
ities. Although we have chosen to exclude these variable
costs from our analysis, the investments needed to estab-
lish a cold chain facility may be available at the program
level and will be important considerations for program
planners to include. In addition, because entire bottles of
liquid formulation must be dispensed monthly, often ex-
ceeding the total needed quantity, there will likely be some
wastage associated with the distribution of liquid drugs.
Our current methodology excludes wastage costs, but
these will need to be considered by program planners as
well. Our costs estimates, however, will allow providers to
incorporate drug-related pediatric ART costs into their
existing budget and thus permit this methodology to apply
to a variety of clinical settings. And finally, pediatric ART
costs will likely change over time with the addition of new
formulations of existing drugs or the development of new
pediatric and adult medications. For example, LPV/r
sprinkles and modifiable-dose ARV sachets are currently
under development [37]. These formulations may improve
tolerability and dosing flexibility, and also may also re-
move storage requirements that are a significant barrier to
scale up of LPV/r use. A cost estimate has not yet been
released for these formulations, but will be necessary to
determine their cost effectiveness in the context of other
available ARV options [37]. The methodology described
here can be used as a framework for these and other drug
developments in the future.
Conclusions
The number of children living with HIV is growing each
year, and will likely continue to grow until efforts to
prevent perinatal HIV infection reach target goals [38].
Antiretroviral therapy has been shown to drastically re-
duce morbidity and mortality in children with HIV, yet
questions about when to start treatment and what treat-
ment to start remain key issues for policy makers [2,39].
In order to thoroughly examine these questions, one
must be able to accurately assess the costs of pediatric
antiretroviral therapy. We hope that the methodology
outlined in this paper can be used as a standardized ap-
proach for budget administrators and cost-effectiveness
analysts, who seek to increase pediatric ARTavailability in
a constrained budget environment and that our detailed
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pediatric drug costing across methodologies and evalua-
tions. This costing procedure can be modified to reflect
ARV prices and available formulations that are most rep-
resentative for a range of programs and settings, and thus
can aid budget analysts in developing more cost-effective
recommendations for pediatric ART.
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